Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 3Leukemia 2Burkitt Lymphoma 2Recurrence 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Bites and Stings 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × blinatumomab × Clear all
NCT03173430 2020-02-07

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Terminated
6 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡